Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5542264 | 0.88 | KMT2A (0.60) | SMN1; SMN2ALDH1A1HSD17B10TSHRHPGD | |
| SCHEMBL577432 | 0.83 | SMN1; SMN2 (0.67) | SMN1; SMN2ALDH1A1PKMHSD17B10GLA | |
| SCHEMBL2689400 | 0.82 | SLC7A11 (0.63) | ALDH1A1LMNATSHRMAPK1MAPT | |
| SCHEMBL5541967 | 0.80 | NR1H3 (0.54) | ALDH1A1 | |
| SCHEMBL5540729 | 0.77 | NR1H3 (0.50) | — | |
| SCHEMBL5539344 | 0.77 | NR1H3 (0.47) | MEN1KMT2A | |
| SCHEMBL5542353 | 0.75 | NR1H3 (0.52) | SMN1; SMN2ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL10085968 | 0.72 | NR1H3 (0.43) | MEN1KMT2A | |
| SCHEMBL12931735 | 0.71 | CA12 (0.59) | SMN1; SMN2ALDH1A1HSD17B10TSHRGAA | |
| SCHEMBL10085967 | 0.71 | KMT2A (0.62) | SMN1; SMN2ALDH1A1PKMHSD17B10BRCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115817-A1 | PHTHALIMIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY COMPOUNDS AND/OR TNF-ALPHA MODULATORS, METHOD FOR PRODUCING SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND USES THEREOF FOR THE TREATMENT OF INFLAMMATORY DISEASES | EMS S.A. (BR) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115817-A1 | PHTHALIMIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY COMPOUNDS AND/OR TNF-ALPHA MODULATORS, METHOD FOR PRODUCING SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND USES THEREOF FOR THE TREATMENT OF INFLAMMATORY DISEASES | TNF, PER2, CRY1 | SMN1; SMN2 4021/4885ALDH1A1 1677/4885PKM 1557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.